Business Description
Verrica Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92511W1080
Description
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.53 | |||||
| Equity-to-Asset | 0.24 | |||||
| Debt-to-Equity | 2.3 | |||||
| Debt-to-EBITDA | -0.73 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.76 | |||||
| Beneish M-Score | 6.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | 12.2 | |||||
| 3-Year Book Growth Rate | -28.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.76 | |||||
| 9-Day RSI | 49.64 | |||||
| 14-Day RSI | 56.33 | |||||
| 6-1 Month Momentum % | 34.57 | |||||
| 12-1 Month Momentum % | -18.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | |||||
| Quick Ratio | 4.49 | |||||
| Cash Ratio | 4.09 | |||||
| Days Inventory | 318.27 | |||||
| Days Sales Outstanding | 203.78 | |||||
| Days Payable | 736.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -10.64 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.44 | |||||
| Operating Margin % | -1233.82 | |||||
| Net Margin % | -1307.48 | |||||
| FCF Margin % | -759.93 | |||||
| ROE % | -150.66 | |||||
| ROA % | -94.54 | |||||
| ROIC % | -713.33 | |||||
| ROC (Joel Greenblatt) % | -1196.89 | |||||
| ROCE % | -100.35 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 59.48 | |||||
| PB Ratio | 14.15 | |||||
| Price-to-Tangible-Book | 14.15 | |||||
| EV-to-EBIT | -4.19 | |||||
| EV-to-EBITDA | -4.24 | |||||
| EV-to-Revenue | 51.52 | |||||
| EV-to-Forward-Revenue | 9.45 | |||||
| EV-to-FCF | -6.78 | |||||
| Price-to-Net-Current-Asset-Value | 17.97 | |||||
| Price-to-Net-Cash | 36.94 | |||||
| Earnings Yield (Greenblatt) % | -23.87 | |||||
| FCF Yield % | -13.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRCA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verrica Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5.124 | ||
| EPS (TTM) ($) | -1.47 | ||
| Beta | 1.73 | ||
| Volatility % | 110.8 | ||
| 14-Day RSI | 56.33 | ||
| 14-Day ATR ($) | 0.335633 | ||
| 20-Day SMA ($) | 6.708 | ||
| 12-1 Month Momentum % | -18.39 | ||
| 52-Week Range ($) | 2.86 - 7.755 | ||
| Shares Outstanding (Mil) | 42.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verrica Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verrica Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verrica Pharmaceuticals Inc Frequently Asked Questions
What is Verrica Pharmaceuticals Inc(VRCA)'s stock price today?
The current price of VRCA is $6.65. The 52 week high of VRCA is $7.76 and 52 week low is $2.86.
When is next earnings date of Verrica Pharmaceuticals Inc(VRCA)?
The next earnings date of Verrica Pharmaceuticals Inc(VRCA) is 2024-05-09 Est..
Does Verrica Pharmaceuticals Inc(VRCA) pay dividends? If so, how much?
Verrica Pharmaceuticals Inc(VRCA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers